DUBLIN--(BUSINESS WIRE)--The "Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Neuromyelitis Optica - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuromyelitis Optica (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 2, 5, 10, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Neuromyelitis Optica (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuromyelitis Optica (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuromyelitis Optica (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
Neuromyelitis Optica - Overview
Neuromyelitis Optica - Therapeutics Development
Neuromyelitis Optica - Therapeutics Assessment
Neuromyelitis Optica - Companies Involved in Therapeutics Development
Neuromyelitis Optica - Drug Profiles
Neuromyelitis Optica - Dormant Projects
Neuromyelitis Optica - Discontinued Products
Neuromyelitis Optica - Product Development Milestones
Appendix
Companies Mentioned
- Accendatech Au Pty Ltd
- Accure Therapeutics SL
- Ahead Therapeutics SL
- Alexion Pharmaceuticals Inc
- Aprilbio Co Ltd
- Apsara Therapeutics
- Bio-Thera Solutions Ltd
- Biogen Inc
- Boston Pharmaceuticals Inc
- Chord Therapeutics Sarl
- Chugai Pharmaceutical Co Ltd
- Cour Pharmaceuticals Development Co Inc
- Endece LLC
- EnhanX Biopharm Inc
- H. Lundbeck AS
- HanAll Biopharma Co Ltd
- ImCyse SA
- Imstem Biotechnology Inc
- LFB SA
- Mitsubishi Tanabe Pharma Corp
- Nanjing Iaso Biotherapeutics Co Ltd
- NovelMed Therapeutics Inc
- Orion BioScience Inc
- RemeGen Ltd
- Tolerion Inc
- Viela Bio Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pa3mee
